Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases

Table 1 Clinical characteristics of patients with colorectal liver metastasis

Characteristic	CRLM with FOLFOX1(n = 53)	CRLM without FOLFOX2(n = 29)
Localization of primary tumor
Colon	25	13
Rectum	28	16
Gender
Male	29	17
Female	24	12
Age at surgery (yr)
Median	61.4	66.7
Range	35-79	43-77
Largest tumor diameter (cm)
Median	4.7	4.9
Range	1.3-9.7	1.2-10.1
Tumor (T)-category
of primary tumor
pT1	2	6
pT2	6	2
pT3	40	19
pT4	5	2
Lymph node metastasis (N-category)3
Positive	40	10
Negative	13	19
Grade
G1	0	1
G2	32	17
G3	21	11

¹Colorectal cancer patients with FOLFOX chemotherapy before colorectal cancer liver metastasis (CRLM) surgery;

²Colorectal cancer patients without FOLFOX chemotherapy before CRLM surgery;

³N-category significantly different between FOLFOX and non-FOLFOX patients (P < 0.05).

Table 2 Period between resection of primary tumor and resection of colorectal liver metastasis

Interval	CRLM with FOLFOX1(n = 53)	CRLM without FOLFOX2 (n = 29)
< 6 mo	7	8
≥ 6 mo	45	21
0	1	0

¹Colorectal cancer patients with FOLFOX chemotherapy before colorectal cancer liver metastasis (CRLM) surgery;

²Colorectal cancer patients without FOLFOX chemotherapy before CRLM surgery.